Q1 FY26 Earnings Presentation Aug 6, 2025 Cautionary Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, regarding LiveRamp's (the "Company") future business prospects. These statements involve risks and uncertainties that could cause the Company's actual results to differ materially, including, but not limited to competit ...

2Q25 Earnings Presentation August 6, 2025 Published by: Sinclair, Inc. 111 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures of Sinclair, Inc. (the "Company"), including Adjusted EBITDA, which are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP") (collectively, the "non-GAAP financial measures"). Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization, and non-recurring and unusual transaction, implementa ...

1 2 Confidential & Proprietary – Do not distribute. © 2024 Zevia PBC 3 Source: Confidential & Proprietary – Do not distribute. © 2024 Zevia PBC 4 1Numerator Shopper Metrics Report for 12M ending 06/30/2025 which incorporates expanded scope of BFY Soda Brands in 2Q25 4 • • • • • | 2025 | Net Sales | Gross Margin | Net Loss | Adjusted EBITDA¹ | | --- | --- | --- | --- | --- | | 02 | $44.5 million +10.1% vs. PY | 48.7% +680 basis points vs. PY | -$0.7 million +$6.3 million vs. PY | +$0.2 million +$4.6 million ...

Financial Performance - Total revenue decreased by 8% year-over-year to $248.2 million in Q2 2025[25] - Bumble App revenue decreased by 8% year-over-year to $201.4 million in Q2 2025[25] - The company reported a net loss of $367 million in Q2 2025[25] - Adjusted EBITDA increased by 26% year-over-year to $94.6 million in Q2 2025, with an Adjusted EBITDA margin of 38.1%[25, 48] User Metrics - Total paying users decreased by 9% year-over-year to 3.8 million in Q2 2025[25] - Bumble App paying users decreased by 11% year-over-year to 2.5 million in Q2 2025[25] - Total Average Revenue per Paying User (ARPPU) increased by 1% year-over-year to $21.69 in Q2 2025[25] - Badoo App and Other paying users decreased by 3% year-over-year[36] Future Outlook - The company expects total revenue of $240-$248 million for Q3 2025[44] - Bumble App revenue is projected to be $194-$200 million for Q3 2025[44] - Adjusted EBITDA is expected to be $79-$84 million for Q3 2025[44]

Financial Performance - Total revenue reached $54.8 million, a 16% increase compared to the second quarter of 2024[10] - Software revenue grew by 15% to $40.5 million[10] - Drug discovery revenue increased by 19% to $14.2 million[10] - Cash and marketable securities increased by 21% to $462.3 million as of June 30, 2025[28] - Deferred revenue surged by 289% to $186.5 million[28] Guidance and Outlook - The company maintains its software growth and drug discovery revenue guidance[10] - Operating expenses are expected to be lower than in 2024[10] - Third-quarter software revenue is projected to be between $36 million and $40 million[10] - The company anticipates software revenue to increase by 10%–15% in 2025[31] - Drug discovery revenue is projected to be between $45 million and $50 million in 2025[31] Pipeline and Development - Initial Phase 1 data for SGR-1505 was presented in June, with strategic opportunities for clinical development being explored[11] - Initial Phase 1 data for SGR-2921 and SGR-3515 are expected in the fourth quarter of 2025[11]

Q3 FY25 Performance Highlights - The company achieved record Q3 and Year-to-Date GAAP and Non-GAAP EPS [12] - Significant margin expansion was observed during the quarter [12] - There was a major improvement in workplace safety performance [12] Financial Results - Q3 net sales were $960.913 million [49] - GAAP gross margin was 34.6% [49] - Non-GAAP operating income was $139.041 million [49] - Adjusted EBITDA reached $166.568 million [50] Segment Performance - Pet segment net sales were $493 million with a non-GAAP operating margin of 15.8% [28] - Garden segment net sales were $468 million with a non-GAAP operating margin of 18.2%, up 310 bps [29, 30] Outlook - The company reaffirmed fiscal year 2025 non-GAAP EPS guidance of approximately $2.60 [15]

Q2 2025 Earnings Call August 6, 2025 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forwa ...

Market Opportunity & Financial Performance - The quantum computing and networking market is projected to create up to $880 billion in economic value by 2040[8] - IonQ anticipates FY25 revenue between $82 million and $100 million[12] - The company's cash, cash equivalents, and investments balance was $697 million as of March 31, 2025[12] Technology & Roadmap - IonQ is targeting 2 million qubits and 80,000 logical qubits by 2030[10] - The company plans to release a 100-qubit system in 2025[10] - IonQ's error correction overhead is exceedingly low at 13:1[10] Expansion & Acquisitions - IonQ has been expanding its global footprint across 5 countries[10] - The company intends to acquire Oxford Ionics, with the agreement signed in June 2025[12] - IonQ acquired a majority stake in ID Quantique in April 2025[14] Applications & Partnerships - Quantum machine learning applications are expected to impact most industries[9] - Ansys simulation times improved by up to 12% using IonQ's quantum solution[58] - AstraZeneca simulations achieved 20x faster time-to-solution using IonQ's quantum solution[59]

Second Quarter 2025 Results August 6, 2025 Forward-looking Statements This presentation contains, and of Warrior Met Coal, Inc.'s (the "Company", "WMC" or "Warrior") officers and representatives may from time to time make, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this presentation that address activities, eve ...

Corporate Overview Presentation August 2025 2025 Vir Biotechnology, Inc. 1 Legal disclaimer Forward-Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the therapeutic and commercial potential of Vir Biotechnology's CHD program, as well as Vir Biotechnology's strategy, plans and expectations related thereto; the therapeutic and commercial potential of V ...